Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $25→$26 | ― | 11.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $40→$38 | ― | 11.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $60 | ― | 5.00% | Reiterated | ||||
 | Arcutis Biotherapeutics | BUY $20 | ― | -2.80% | Reiterated | Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (NASDAQ: ARQT) and AMN Healthcare Services (NYSE: AMN) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $84→$70 | ― | 0.90% | Reiterated | ||||
 | Helmerich & Payne | HOLD $28→$26 | ― | -3.20% | Reiterated | Helmerich & Payne (HP) Gets a Hold from TD Cowen | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $12 | ― | 2.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $73→$59 | ― | 0.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $1.9→$1.75 | ― | 7.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $53 | ― | 4.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $15→$12.5 | ― | 2.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $324 | ― | 2.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $50→$65 | ― | 21.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $6 | ― | 12.60% | Reiterated | ||||
 | PSQ Holdings | BUY $4 | ― | -20.50% | Reiterated | Roth MKM Sticks to Its Buy Rating for PSQ Holdings (PSQH) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $16 | ― | 21.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $4.35 | ― | 16.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $110 | ― | 14.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $360 | ― | 10.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $185→$208 | ― | 12.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $29→$30 | ― | 21.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $12.5→$12 | ― | 11.40% | Reiterated | ||||
| Real Brokerage | BUY $8→$7.5 | ― | -20.50% | Reiterated | Analysts Offer Insights on Real Estate Companies: Real Brokerage (NASDAQ: REAX) and Invesco Mortgage (NYSE: IVR) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $7→$5 | ― | 14.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $40 | ― | 6.60% | Reiterated | ||||
Argenx Se | BUY $803 | ― | -18.60% | Reiterated | Argenx Se (ARGX) Receives a Buy from Citi | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $10.65→$11.25 | ― | 2.00% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $150 | ― | 25.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $217 | ― | 0.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $45→$49 | ― | 0.90% | Reiterated | ||||
| Sarepta Therapeutics | BUY $190→$85 | ― | 0.00% | Reiterated | Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and TransMedics Group (NASDAQ: TMDX) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $45→$44 | ― | 5.10% | Reiterated | ||||
 | Arhaus | BUY $13 | ― | -7.50% | Reiterated | Barclays Remains a Buy on Arhaus (ARHS) | |||
| Innovex International | SELL $16→$13 | ― | -3.90% | Reiterated | Barclays Sticks to Their Sell Rating for Innovex International (INVX) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $13→$14 | ― | 15.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $2 | ― | 4.50% | Reiterated | ||||
 | APA | HOLD $19 | ― | -3.60% | Reiterated | Barclays Sticks to Its Hold Rating for APA (APA) | |||
| California Resources Corp | HOLD $47→$50 | ― | -3.60% | Reiterated | Barclays Reaffirms Their Hold Rating on California Resources Corp (CRC) | |||
| Conocophillips | BUY $120 | ― | -3.60% | Reiterated | Analysts' Opinions Are Mixed on These Energy Stocks: Pembina Pipeline (NYSE: PBA), Valvoline (NYSE: VVV) and Conocophillips (NYSE: COP) | |||
| Murphy Oil | SELL $24→$22 | ― | -3.60% | Reiterated | Barclays Sticks to Its Sell Rating for Murphy Oil (MUR) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $26 | ― | 2.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $2 | ― | 2.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $10→$5 | ― | 11.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $115 | ― | 6.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $2→$3 | ― | 9.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $56 | ― | 6.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $249 | ― | 6.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $3 | ― | 11.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $75→$76 | ― | 8.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $212 | ― | 6.10% | Reiterated |
Rows:
